Alnylam Pharma (ALNY) Income Statement

Click line-items for a historical chart and %

Net revenues from research collaborators	8.71M
Research and development	83.17M
General and administrative	17.99M
Total operating expenses	101.16M
Loss from operations	-92.45M
Equity in loss of joint venture (Regulus Therapeutics Inc.)
Interest income
Other (expense) income	229K
Total other income (expense)	2.32M
Loss before income taxes
Benefit from income taxes
Net loss	-90.13M
Net loss per common share - basic and diluted	-1.05
Weighted average common shares used to compute basic and diluted net loss per common share
Net loss	-90.13M
Foreign currency translation
Unrealized (loss) gain on marketable securities	-18.33M
Comprehensive loss	-109.41M
Research and development
General and administrative

Entities mentioned with ALNY

View All Entities